12:00 AM
 | 
Mar 07, 2016
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Allob: Phase IIa data

Data from the first patient with symptomatic degenerative lumbar disc disease that required interbody fusion in an open-label, Belgian Phase IIa trial showed that a single implantation of Allob mixed with bioceramic granules into the lumbar interbody fusion site led...

Read the full 176 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >